Navigation Links
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
Date:6/30/2011

VA149; the combination of NVA237 with Novartis' once-daily, long-acting beta2-agonist (LABA), indacaterol, is planned for 2013.  Indacaterol is now approved in more than 50 countries and available in more than 20, with US approval dependent on an FDA decision expected in July 2011. 

Notes for Editors:

About COPD

COPD is a chronic obstruction of the airways which affects 210 million people worldwide[1] and is projected to be the third leading cause of death by 2020[2].  It is a progressive lung disease with symptoms including chronic bronchitis and/or emphysema, which slowly progresses and eventually leads to a largely irreversible loss of lung function.  While there is no cure, bronchodilators such as LAMAs and LABAs make breathing easier by enlarging the patient's airways, and are recognised in international guidelines as an integral part of the treatment for COPD.

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.

For further information about Sosei, please visit http://www.sosei.com/.

Forward-Looking Statements

This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and serv
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
2. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
11. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Inhibikase Therapeutics, Inc., an emerging ... it will present new results on its antiviral ... sponsored by the PML Consortium (composed of Pfizer, ... (JCV) is the causative agent of Progressive Multifocal ... in an extended release formulation, can clear JC ...
(Date:5/23/2013)... , May 23, 2013  Echo Pharma Acquisition Limited ... waive down the Acceptance Threshold from 90 percent to ... Elan Share in accordance with the terms of the ... summarized below. Under the terms of the ... (NYSE: ELN ) for $12.50 per share ...
(Date:5/23/2013)... 2013   BioLife Solutions , Inc. (OTC:BLFS), a ... hypothermic storage and cryopreservation freeze ... media manufacturer , today announced its participation at the ... 2013 this week in London ... Dr. Aby J. Mathew, BioLife,s Senior Vice President and ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3
... May 23, 2011 Heska Corporation (NASDAQ: ... Humphrey Annual Veterinary and Dental Conference on Wednesday, June 1, 2011. ... 119 West 56th Street in New York City and is scheduled ... http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) About Heska ...
... May 23, 2011 Singapore company Novus Scientific Pte. ... Closure After Lipectomy, TRAM/DIEP Flap - Comparison of TIGR® ... 20 patient mark, representing approximately one quarter of the ... multi-center, randomized trial involves University of California San Diego ...
Cached Medicine Technology:Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons 2
(Date:5/23/2013)... Minn. -- Mayo Clinic researchers have used next generation ... aggressive prostate cancer tumors have similar genetic origins, which ... online today in the journal Cancer Research . ... alterations using next generation sequencing in adjacent Gleason patterns ... with changes in pathology," says ,John Cheville, M.D., Mayo ...
(Date:5/23/2013)... Transvaginal mesh lawsuit claims ... move forward in a federal multidistrict litigation underway in ... Liebhard LLP reports. In an Order issued on ... Bard to seal emails that included supplier information the ... proprietary information about its suppliers. The emails were filed ...
(Date:5/23/2013)... May 23, 2013 The vast majority ... deal of control over their level of physical activity, ... far fewer are actually taking that control. Those ... Council (IFIC) Foundation’s 2013 Food & Health Survey. , ... it’s possible to have “a great deal of control” ...
(Date:5/23/2013)... Fort Myers, FL (PRWEB) May 23, 2013 ... daring prediction in the midst of growing numbers of H7N9 ... of UV-Aid, Predict H7N9 Bird Flu Cases Will Subside in ... of May 13th no new cases have been reported. ... of the flu is as predictable as flowers budding in ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Cheap Concert Tickets ... the Summer of 2013 at stadiums throughout North America. ... board on Paul McCartney concert tickets to help McCartney fans ... of Cheap Concert Tickets, states that she is also offering ... concert tickets. Being a baby boomer, she is also ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2
... MD, Launch Daily Syndicated ... Newspaper Column, SAN DIEGO ... to keep the health momentum going than the YOU Docs,Michael Roizen, MD, ... Oprah Winfrey Show. King Features Syndicate and,RealAge.com announce the launch of a ...
... TORRANCE, Calif., May 5 A landmark study shows,dangerous ... breast milk,but can be significantly reduced by Chlorella pyrenoidosa., ... Food, analyzed dioxin,levels in breast milk from 35 pregnant ... pyrenoidosa supplements. The study showed toxic levels,were significantly lower ...
... Ill., May 5 With spring in the ... all the essentials that warm weather,brings -- flip ... The available options in sunscreen protection have become ... application,or enhanced protection from ultraviolet (UV) light. Fortunately,dermatologists ...
... Marjorie Greenfield, M.D.,obstetrician- gynecologist at University ... week with The Working Woman,s,Pregnancy Book., ... physical and,emotional changes of each trimester, to ... this up-to-date guide discusses in a warm ...
... by which the epidermal growth factor receptor (EGFR), a ... kinase-independent mechanism. The research, published by Cell Press in ... a rationale for the less than impressive results of ... activity and suggests new directions for potential therapeutic strategies. ...
... Recovering sex addict Michael Leahy tells his personal story ... CHICAGO, May 5 It is accessible from,anywhere. ... of work, and,even our homes. An estimated 40 million ... the 2006 revenues of sex and,the porn industry in ...
Cached Medicine News:Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 2Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 3Health News:Recent Advances Make Sunscreen More Effective and Easier to Use 2Health News:Recent Advances Make Sunscreen More Effective and Easier to Use 3Health News:Recent Advances Make Sunscreen More Effective and Easier to Use 4Health News:Recent Advances Make Sunscreen More Effective and Easier to Use 5Health News:Recent Advances Make Sunscreen More Effective and Easier to Use 6Health News:University Hospitals Physician Authors Working Woman's Pregnancy Book 2Health News:EGFR protects cancer cells from starvation via a kinase-independent mechanism 2Health News:Porn Nation Uncovers the Sexualization of America 2
... of the first steps any hospital or ... the most powerful, most effective tools available ... CliniComps world-class clinician documentation and electronic medical ... systems achieve this goal. In fact, its ...
... Care, the world-class clinician documentation and electronic ... focus on the specific needs of intensive ... Its broad, deep clinical functionality has secured ... EMR solution in critical care, and its ...
... very popular only a few are really ... Explore why MediTalk is rapidly becoming the ... administrators. An EMR designed by physicians from ... patients quickly and efficiently while improving workflow ...
MediNotes e is an EMR design which utilizes a "tab concept for navigation. MediNotes e can display multiple patients, encounter notes, workflow items, patient flow, messages, alerts, and more, all in...
Medicine Products: